Reneo Pharmaceuticals (RPHM) Stock Forecast, Price Target & Predictions
RPHM Stock Forecast
Reneo Pharmaceuticals stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
RPHM Analyst Ratings
According to 1 Wall Street analysts, Reneo Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RPHM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Reneo Pharmaceuticals's last stock rating was published by Piper Sandler on May 17, 2022. The company gave RPHM a "Overweight" rating, the same as its previous rate.
Reneo Pharmaceuticals Financial Forecast
Reneo Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| High Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| Low Forecast | $15.96M | $7.97M | - | - | $100.25K | $27.25K | - |
| # Analysts | 1 | 1 | - | - | 1 | 1 | - |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RPHM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Reneo Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | 1 | 1 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict RPHM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Reneo Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Reneo Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | 1 | 1 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| High Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| Low Forecast | $-6.35M | $-10.34M | $-16.82M | $-18.83M | $-2.34M | $-2.34M | $-3.34M |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RPHM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Reneo Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | 1 | 1 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Reneo Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RPHM last annual SG&A of $NaN (undefined).
Reneo Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | 1 | 1 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| High Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| Low Forecast | $-0.19 | $-0.31 | $-0.50 | $-0.56 | $-0.07 | $-0.07 | $-0.10 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Reneo Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RPHM previous annual EPS of $NaN (undefined).
Reneo Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| NKTX | Nkarta | $2.27 | $21.60 | 851.54% | Buy |
| HOWL | Werewolf Therapeutics | $1.64 | $12.00 | 631.71% | Buy |
| PRME | Prime Medicine | $2.91 | $17.25 | 492.78% | Buy |
| CCCC | C4 Therapeutics | $4.05 | $20.00 | 393.83% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | |
| VIR | Vir Bio | $7.35 | $28.00 | 280.95% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| IMMX | Immix Biopharma | $2.29 | $7.00 | 205.68% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| KZR | Kezar Life Sciences | $6.52 | $17.50 | 168.40% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RPRX | Royalty Pharma | $25.12 | $51.00 | 103.03% | Buy |
| ADPT | Adaptive Bio | $6.52 | $12.33 | 89.11% | Hold |
| SMMT | Summit Therapeutics | $18.57 | $35.00 | 88.48% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| DNA | Ginkgo Bioworks | $9.61 | $7.00 | -27.16% | Buy |